Advances in novel hormonal agents for metastatic prostate cancer
10.3760/cma.j.cn112330-20210908-00002
- VernacularTitle:转移性前列腺癌新型内分泌药物治疗进展
- Author:
Zhiquan HU
1
;
Jiahua GAN
;
Jihua TIAN
Author Information
1. 华中科技大学同济医学院附属同济医院泌尿外科，武汉 430030
- Keywords:
Metastatic prostate cancer;
Ndocrine therapy;
Drugs
- From:
Chinese Journal of Urology
2021;42(Z2):3-6
- CountryChina
- Language:Chinese
-
Abstract:
With the economic development and medical progress in China, the incidence of prostate cancer is increasing, and most patients have already developed advanced tumors with poor prognosis when diagnosed. The main cornerstone of treatment for metastatic hormone-sensitive prostate cancer (mHSPC) has always been androgen deprivation therapy (ADT), but most mHSPC will transform into metastatic castration-resistant prostate cancer (mCRPC), how to prolong the time from mHSPC to mCRPC has become a current research hotspot, and several landmark phase 3 clinical trials in recent years have led to rapid changes in patient treatment options, including a variety of drugs with different mechanisms of action (e.g., endocrine therapy, chemotherapy, radiotherapy, immunotherapy, and targeted therapy). This article will focus on the current status and progress of novel endocrine agents in metastatic prostate cancer for clinical use.
